<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03005015</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1528</org_study_id>
    <nct_id>NCT03005015</nct_id>
  </id_info>
  <brief_title>Lenvatinib in Second Line Endometrial Carcinoma</brief_title>
  <official_title>A Randomized Phase II Study of Lenvatinib Versus Doxorubicin in Second Line Advanced or Recurrent Endometrial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this multicenter, randomized phase II trial is to assess the&#xD;
      efficacy, as measured by progression-free survival (PFS), of lenvatinib compared to&#xD;
      doxorubicin in advanced or recurrent endometrial cancer.&#xD;
&#xD;
      The main secondary objective is to evaluate the predictive value of Ang-2 on lenvatinib&#xD;
      activity and establishing a cutoff value as potential selection criteria for phase III.&#xD;
&#xD;
      Other secondary objectives are to assess the tolerability and safety of lenvatinib in this&#xD;
      setting and overall survival, response and disease control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    supporting company (Eisai) withdrew their interest&#xD;
  </why_stopped>
  <start_date>January 2017</start_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>2.5 years</time_frame>
    <description>PFS assessed by Response Evaluation Criteria in Solid Tumors (RECIST</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Endometrial Neoplasms</condition>
  <arm_group>
    <arm_group_label>Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenvatinib 24 mg orally every day. Treatment is continued until unacceptable toxicity, progressive disease or patient withdrawal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxorubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doxorubicin 60 mg/m² iv bolus every 3 weeks. Treatment is continued for a maximum of 6 cycles or until unacceptable toxicity, progressive disease or patient withdrawal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <arm_group_label>Lenvatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <arm_group_label>Doxorubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female subjects age ≥18 years at the time of informed consent&#xD;
&#xD;
          -  World Health Organization (WHO) Performance Status of 0 or 1&#xD;
&#xD;
          -  Patients with histologically confirmed endometrial cancer including serous-papillary&#xD;
             and clear cell histologies. Uterine carcinosarcomas are allowed.&#xD;
&#xD;
          -  Radiographic evidence of disease progression according to RECIST 1.1 after 1 prior&#xD;
             systemic, platinum-based chemotherapy regimen for metastatic or primary unresectable&#xD;
             endometrial carcinoma for which no surgical or radiotherapy treatment options exist.&#xD;
&#xD;
          -  Patients with disease progression following platinum-based chemotherapy administered&#xD;
             as either adjuvant or neoadjuvant treatment are also eligible.&#xD;
&#xD;
          -  Patients may have received prior radiotherapy and / or adjuvant chemotherapy for early&#xD;
             high-risk disease&#xD;
&#xD;
          -  Patients may not have received prior treatment with anthracyclines&#xD;
&#xD;
          -  Blood samples available for retrospective central assessment of Ang-2 level&#xD;
&#xD;
          -  Patients may have had prior therapy providing the following conditions are met:&#xD;
&#xD;
          -  Surgery and radiation therapy: wash-out period of 14 days and subjects must have&#xD;
             recovered adequately from any toxicity and/or complications from radiotherapy and&#xD;
             major surgery prior to starting therapy.&#xD;
&#xD;
          -  Systemic anti-tumor therapy or any investigational agent: wash-out period of 21 days&#xD;
             (or 5 x half-life)&#xD;
&#xD;
          -  Recovery from any toxic effects of prior therapy to ≤ Grade 1 per the National Cancer&#xD;
             Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v4.) except&#xD;
             alopecia&#xD;
&#xD;
          -  Adequate contraceptive measures&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inadequate hematologic, renal and hepatic functions&#xD;
&#xD;
          -  Abnormal cardiac function&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Casado</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario San Carlos, Madrid, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>December 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2016</study_first_posted>
  <last_update_submitted>December 23, 2016</last_update_submitted>
  <last_update_submitted_qc>December 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

